Colorectal Liver Metastases (CRCLM)

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Colorectal Liver Metastases (CRCLM) trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 2

NCT06590259

A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM

The goal of this study is to evaluate the efficacy and safety of multi-mode ablation combined with systemic therapy including PD-1(programmed death receptor 1)…

China20 participantsStarted 2024-03-12

Treatment: Multi-mode tumor treatment system, Sintilimab+mFOLFOX6 or FOLFIRI+bevacizumab or cetuximab

All recent trials (8 shown)

Not Yet RecruitingNot Applicable

NCT07406126

Yttrium-90 Radioembolization Neoadjuvant Therapy With Immune Marker Profiling and Dosimetry for Potentially Resectable P…

This is a observational, prospective, single arm, proof of concept study to assess safety, feasibility, and potential efficacy of combining Yttrium-90 transarte…

Spain30 participantsStarted 2026-02

Treatment: Yttrium-90 Radioembolization with standard systemic therapy

Active — Not RecruitingNot Applicable

NCT06199232

Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment

Hepatic arterial infuison chemothearpy (HAIC), targeted therapy, and programmed death-1 (PD-1) inhibitors have been demonstrated to be effective for colorectal…

China47 participantsStarted 2024-01-23

Treatment: HAIC+targeted therapy+PD-1 inhibitor

Colorectal Liver Metastases (CRCLM)

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM

All recent trials (8 shown)

Yttrium-90 Radioembolization Neoadjuvant Therapy With Immune Marker Profiling and Dosimetry for Potentially Resectable P…

Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM

All recent trials (8 shown)

Yttrium-90 Radioembolization Neoadjuvant Therapy With Immune Marker Profiling and Dosimetry for Potentially Resectable P…

Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment

Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM

To Evaluate the Performance of HepaSphere Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemot…

FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM

A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM

Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM